LT3535263T - Pakeistieji pirido[3,4-b]indolai, skirti kremzlių pokyčių gydymui - Google Patents

Pakeistieji pirido[3,4-b]indolai, skirti kremzlių pokyčių gydymui

Info

Publication number
LT3535263T
LT3535263T LTEP17794307.3T LT17794307T LT3535263T LT 3535263 T LT3535263 T LT 3535263T LT 17794307 T LT17794307 T LT 17794307T LT 3535263 T LT3535263 T LT 3535263T
Authority
LT
Lithuania
Prior art keywords
indoles
treatment
cartilage disorders
substituted pyrido
pyrido
Prior art date
Application number
LTEP17794307.3T
Other languages
English (en)
Inventor
Dirk Gretzke
Olaf Ritzeler
Uwe Heinelt
Volkmar Wehner
Friedemann Schmidt
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of LT3535263T publication Critical patent/LT3535263T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP17794307.3T 2016-11-07 2017-11-02 Pakeistieji pirido[3,4-b]indolai, skirti kremzlių pokyčių gydymui LT3535263T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306452.0A EP3318563A1 (en) 2016-11-07 2016-11-07 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
PCT/EP2017/078026 WO2018083157A1 (en) 2016-11-07 2017-11-02 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Publications (1)

Publication Number Publication Date
LT3535263T true LT3535263T (lt) 2020-12-28

Family

ID=57286428

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17794307.3T LT3535263T (lt) 2016-11-07 2017-11-02 Pakeistieji pirido[3,4-b]indolai, skirti kremzlių pokyčių gydymui

Country Status (35)

Country Link
US (3) US11130755B2 (lt)
EP (3) EP3318563A1 (lt)
JP (1) JP7046063B2 (lt)
KR (1) KR102490199B1 (lt)
CN (1) CN110382496B (lt)
AR (1) AR110136A1 (lt)
AU (2) AU2017353381B2 (lt)
BR (1) BR112019007901A2 (lt)
CA (1) CA3042332A1 (lt)
CL (1) CL2019001251A1 (lt)
CO (1) CO2019005090A2 (lt)
CR (1) CR20190217A (lt)
DK (1) DK3535263T3 (lt)
DO (1) DOP2019000112A (lt)
EA (1) EA038365B1 (lt)
EC (1) ECSP19031458A (lt)
ES (1) ES2837765T3 (lt)
HR (1) HRP20201754T1 (lt)
HU (1) HUE052187T2 (lt)
IL (1) IL265982B (lt)
LT (1) LT3535263T (lt)
MA (1) MA45803B1 (lt)
MX (1) MX2019005308A (lt)
MY (1) MY189589A (lt)
PE (1) PE20191032A1 (lt)
PH (1) PH12019500997A1 (lt)
PT (1) PT3535263T (lt)
RS (1) RS61172B1 (lt)
SG (1) SG11201903195YA (lt)
SI (1) SI3535263T1 (lt)
TN (1) TN2019000143A1 (lt)
TW (1) TWI753966B (lt)
UY (1) UY37473A (lt)
WO (1) WO2018083157A1 (lt)
ZA (1) ZA201902111B (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
EP3717475B1 (en) 2017-11-20 2023-06-07 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3086925A1 (en) 2018-01-05 2019-07-11 Ichan School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
EP3768267A4 (en) * 2018-03-20 2022-04-20 Icahn School of Medicine at Mount Sinai KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
KR20220044721A (ko) * 2019-08-06 2022-04-11 도메인 테라퓨틱스 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물
CN114763347B (zh) * 2021-01-15 2024-06-21 华东师范大学 一类用于诱导间充质干细胞向软骨分化的化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
ECSP951529A (es) 1995-09-05 1997-05-16 Compuestos farmaceuticos
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
JP4599501B2 (ja) 2001-11-07 2010-12-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 多発性骨髄腫および他の癌の処置におけるIκBのインヒビターとしてのカルボリン誘導体
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
JP4626613B2 (ja) * 2004-08-04 2011-02-09 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子
WO2008023063A2 (en) 2006-08-25 2008-02-28 Ares Trading S.A. Treatment of cartilage disorders with fgf-18
WO2008132454A1 (en) 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
WO2010038153A1 (en) 2008-10-01 2010-04-08 The University Of British Columbia Use of sox transcription factor acti\ators for stimulating chondrogenesis
EP2455378A1 (en) * 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
JP5854492B2 (ja) 2011-02-24 2016-02-09 国立大学法人 岡山大学 軟骨細胞分化誘導促進剤
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Also Published As

Publication number Publication date
HRP20201754T1 (hr) 2020-12-25
SG11201903195YA (en) 2019-05-30
MA45803A1 (fr) 2020-05-29
AR110136A1 (es) 2019-02-27
PT3535263T (pt) 2020-12-18
JP7046063B2 (ja) 2022-04-01
EA038365B1 (ru) 2021-08-16
CN110382496A (zh) 2019-10-25
SI3535263T1 (sl) 2020-11-30
EP3318563A1 (en) 2018-05-09
TW201831475A (zh) 2018-09-01
AU2021221468B2 (en) 2023-10-26
JP2019537587A (ja) 2019-12-26
AU2017353381A1 (en) 2019-05-30
US20200095242A1 (en) 2020-03-26
KR20190072654A (ko) 2019-06-25
MY189589A (en) 2022-02-18
DOP2019000112A (es) 2019-07-31
CA3042332A1 (en) 2018-05-11
BR112019007901A2 (pt) 2019-07-02
CO2019005090A2 (es) 2019-07-31
CR20190217A (es) 2019-08-06
CL2019001251A1 (es) 2019-10-04
IL265982A (en) 2019-06-30
MX2019005308A (es) 2019-08-05
TN2019000143A1 (en) 2020-10-05
WO2018083157A1 (en) 2018-05-11
AU2017353381B2 (en) 2021-05-27
MA45803B1 (fr) 2020-10-28
EP3535263A1 (en) 2019-09-11
EP3535263B1 (en) 2020-09-30
US20220041596A1 (en) 2022-02-10
ECSP19031458A (es) 2019-05-31
RS61172B1 (sr) 2021-01-29
HUE052187T2 (hu) 2021-04-28
KR102490199B1 (ko) 2023-01-20
EA201991144A1 (ru) 2019-10-31
CN110382496B (zh) 2022-08-09
UY37473A (es) 2018-06-29
US11130755B2 (en) 2021-09-28
DK3535263T3 (da) 2020-12-21
PH12019500997A1 (en) 2019-08-05
US11827633B2 (en) 2023-11-28
PE20191032A1 (es) 2019-08-05
IL265982B (en) 2021-05-31
US20240182469A1 (en) 2024-06-06
ES2837765T3 (es) 2021-07-01
ZA201902111B (en) 2020-10-28
AU2021221468A1 (en) 2021-09-16
EP3792262A1 (en) 2021-03-17
TWI753966B (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
IL265982A (en) Derivatives of pyrido-[3,4-B]-indole and their use for the treatment of cartilage disorders
HRP20181796T1 (hr) Derivati naftiridina kao antagonisti alfa v beta 6 integrina, namijenjeni liječenju, primjerice, fibrotičnih bolesti
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
HK1245764A1 (zh) 3-取代的5-氨基-6h-噻唑並[4,5-d]嘧啶-2,7-二酮化合物
PL3838274T3 (pl) Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
EP3380471B8 (en) Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders
EP3102036A4 (en) 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
IL267818A (en) Methods for treating neurological disorders
EP3310358A4 (en) COMPOSITIONS AND METHODS FOR TREATING SUBSTANCE ABUSE, SEARCH AND PSYCHIATRIC DISORDER
HK1223916A1 (zh) 作為用於治療神經變性疾病的神經源性藥的吡啶並 吡嗪- -甲酰胺
IL269215A (en) Disubstituted imidazole[4,5-C]quinoline derivatives
EP3229908A4 (en) Gdnf induction for the treatment of retinal disorders
EP3507277B8 (en) Hydroxynorketamine derivatives for the treatment of disorders
TH1601002629A (th) ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท